Immutep Limited
SYDNEY, AUSTRALIA, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutepâ or âthe Companyâ), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number 2016205983) entitled âCombined Preparations for the Treatment of Cancer or Infectionâ by the Australian Patent Office.
This new Australian patent follows the gra...
>>> Read more: Immutep Granted Australian Patent for Eftilagimod Alpha, a Soluble LAG-3 Protein, in Combination with a PD-1 Pathway Inhibitor
SYDNEY, AUSTRALIA, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutepâ or âthe Companyâ), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number 2016205983) entitled âCombined Preparations for the Treatment of Cancer or Infectionâ by the Australian Patent Office.
This new Australian patent follows the gra...
>>> Read more: Immutep Granted Australian Patent for Eftilagimod Alpha, a Soluble LAG-3 Protein, in Combination with a PD-1 Pathway Inhibitor
